Simplified dosing and monitoring of vancomycin for the burn care clinician
- PMID: 1445623
- DOI: 10.1016/0305-4179(92)90032-p
Simplified dosing and monitoring of vancomycin for the burn care clinician
Abstract
Vancomycin has excellent activity against Gram-positive bacteria and is often selected for use in the infected burn patient. Because of multiple-compartment pharmacokinetics, vancomycin serum concentrations can decrease dramatically in a short time period following the end of an intravenous infusion. This accounts for the widely divergent recommendations for serum vancomycin peak concentrations, e.g. from 15 mg/l up to 80 mg/l, when the time for blood sampling following the end of intravenous infusion is different. It is in general not necessary to monitor vancomycin peak concentrations, not only because its toxic potential is overrated but also because potential toxicity and therapeutic efficacy are correlated with trough concentrations. Post-distribution 'peak' concentrations are generally only useful for determining the optimal dosing interval for patients with impaired renal function. A dosing and monitoring paradigm for vancomycin therapy in burned adults has been devised for burn care clinicians. It provides suggested dose and dosing intervals based on body weight and creatinine clearance, with specific recommendations for regimen modification based upon the results of trough serum concentration determinations.
Similar articles
-
Optimizing initial vancomycin dosing in burn patients.Burns. 2011 May;37(3):406-14. doi: 10.1016/j.burns.2010.06.005. Epub 2010 Nov 20. Burns. 2011. PMID: 21095062
-
The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.J Clin Pharm Ther. 2015 Jun;40(3):259-65. doi: 10.1111/jcpt.12270. Epub 2015 Apr 11. J Clin Pharm Ther. 2015. PMID: 25865426 Review.
-
Vancomycin population pharmacokinetics in neonates.Clin Pharmacol Ther. 2000 Apr;67(4):360-7. doi: 10.1067/mcp.2000.105353. Clin Pharmacol Ther. 2000. PMID: 10801244
-
[Continuous administration of vancomycin in patients with severe burns].Presse Med. 1994 Nov 5;23(34):1554-8. Presse Med. 1994. PMID: 7824489 French.
-
Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):259-268. doi: 10.1007/s13318-017-0456-4. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29260505 Review.
Cited by
-
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002. Clin Pharmacokinet. 2005. PMID: 16176116 Review.
-
Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.Eur J Trauma Emerg Surg. 2012 Jun;38(3):301-6. doi: 10.1007/s00068-011-0164-8. Epub 2011 Nov 15. Eur J Trauma Emerg Surg. 2012. PMID: 26815962
-
Occurrence of MRSA endocarditis during linezolid treatment.Eur J Clin Microbiol Infect Dis. 2003 Jun;22(6):372-3. doi: 10.1007/s10096-003-0959-6. Epub 2003 May 27. Eur J Clin Microbiol Infect Dis. 2003. PMID: 12768433 No abstract available.
-
Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role.Infect Drug Resist. 2021 Jul 2;14:2543-2554. doi: 10.2147/IDR.S311231. eCollection 2021. Infect Drug Resist. 2021. PMID: 34239310 Free PMC article.
-
Pharmacokinetic optimisation of vancomycin therapy.Clin Pharmacokinet. 1995 Apr;28(4):327-42. doi: 10.2165/00003088-199528040-00005. Clin Pharmacokinet. 1995. PMID: 7648760 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical